Carregant...

P09.47 Longterm survival after tumor treating fields (TTFields) therapy

Introduction: Glioblastoma multiforme (GBM) is the most common and malignant primary intracranial tumor and traditionally has a median survival of only 10 to 14 months, with only 3 to 5% of patients surviving more than three years. Recurrence (RGBM) is nearly universal, and further decreases the med...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Rulseh, A., Šroubek, J.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5463984/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.303
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!